Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 4,637 matching trials from the live ClinicalTrials.gov search.

Filters: Los Angeles, California Clear all

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Interventions: Cytarabine, Idarubicin Hydrochloride, Navtemadlin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 6
States / cities: Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 2 more

Conditions: Locally Recurrent Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Squamous Cell Carcinoma, Sinonasal Squamous Cell Carcinoma
Interventions: Biopsy Procedure, Birinapant, Computed Tomography, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography; Procedure · Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 33
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 26 more

Conditions: Acute Leukemia
Interventions: IUO Acute Leukemia Panel; Diagnostic Test
Lead sponsor: Becton, Dickinson and Company; Industry
Eligibility: 3 Years and older
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Los Angeles, California • New York, New York • Chapel Hill, North Carolina + 1 more

Conditions: Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity, Squamous Cell Carcinoma of the Oropharynx
Interventions: APG-157; Drug
Lead sponsor: Aveta Biomics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Los Angeles, California • Miami, Florida

Conditions: Chronic Musculoskeletal Pain
Interventions: Emotional Awareness and Expression Therapy, Mindfulness Meditation, Cognitive Behavioral Therapy; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 60 Years to 95 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: West Los Angeles, California • West Haven, Connecticut

Conditions: Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Ductal Adenocarcinoma, Prostate Intraductal Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Biospecimen Collection, Bone Scan, Computed Tomography, Fluciclovine F18, Magnetic Resonance Imaging, Placebo Administration, Positron Emission Tomography, PSMA PET Scan, Relugolix, Stereotactic Body Radiation Therapy; Procedure · Other · Drug + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2034
U.S. locations: 242
States / cities: Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 192 more

Conditions: Sepsis, Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions: ALT-836, Placebo; Drug
Lead sponsor: Altor BioScience; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 20
States / cities: Los Angeles, California • Sacramento, California • Stanford, California + 15 more

Conditions: Congenital Heart Disease in Children, Inflammatory Response
Interventions: Methylprednisolone, Isotonic saline; Drug
Lead sponsor: Kevin Hill; Other
Eligibility: Up to 12 Months
Enrollment: 1,263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 23
States / cities: Los Angeles, California • Aurora, Colorado • Gainesville, Florida + 20 more

Conditions: Large Cell Lymphoma
Interventions: SGN-30; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 13
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 9 more

Conditions: HIV Prevention
Interventions: Tenofovir enema, Saline enema; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Los Angeles, California • Baltimore, Maryland • Pittsburgh, Pennsylvania

Conditions: Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Metastatic Prostate Cancer, Male Urogenital Diseases, Prostatic Diseases, Urogenital Diseases, Male, Genital Diseases, Male, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Genital Neoplasms, Male
Interventions: 18F-Fluciclovine PET/CT Scan; Drug
Lead sponsor: VA Greater Los Angeles Healthcare System; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prostate Cancer
Interventions: MRI-guided Transurethral Ultrasound Ablation; Device
Lead sponsor: Profound Medical Inc.; Other
Eligibility: 45 Years to 80 Years · Male only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 8
States / cities: Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 5 more

Conditions: Heart Failure, Left Ventricular Systolic Dysfunction
Interventions: Vericiguat tablet, Vericiguat suspension, Placebo tablet, Placebo suspension; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 29 Days to 17 Years
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 20
States / cities: Los Angeles, California • Palo Alto, California • San Bernardino, California + 17 more

Conditions: Hemophilia A
Interventions: Nuwiq (low dose protocol), HEMLIBRA, Nuwiq (Atlanta protocol); Drug
Lead sponsor: Emory University; Other
Eligibility: Up to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 8
States / cities: Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 5 more

Conditions: Schizophrenia, Cognition, Psychosis
Interventions: Curcumin, Placebo; Drug
Lead sponsor: VA Greater Los Angeles Healthcare System; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypercholesteremia
Interventions: Gemcabene; Drug
Lead sponsor: NeuroBo Pharmaceuticals Inc.; Industry
Eligibility: 17 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Primary Immune Deficiency Disorder, Osteopetrosis, Cytopenia, Hemoglobinopathy in Children, Anemia, Aplastic
Interventions: BPX-501 T cells, Rimiducid; Biological · Drug
Lead sponsor: Bellicum Pharmaceuticals; Industry
Eligibility: 1 Month to 26 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2034
U.S. locations: 10
States / cities: Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 7 more

Conditions: Neoplasms, Breast Neoplasms, Breast Neoplasms, Triple-Negative, Breast Cancer, Breast Neoplasms, Hormone Receptor Positive/HER2 Negative
Interventions: CX-2009, CX-072; Drug
Lead sponsor: CytomX Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 27
States / cities: La Jolla, California • Los Angeles, California • Santa Monica, California + 22 more

Conditions: Cannabis Use Disorder
Interventions: CUD-AMT, SUD-CBT; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 25 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Placental Disease
Interventions: Not listed
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older · Female only
Enrollment: 199 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Essential Tremor
Interventions: Zonisamide; Drug
Lead sponsor: VA Greater Los Angeles Healthcare System; Federal
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lung Adenocarcinoma, Lung Adenocarcinoma, Mixed Subtype, Lung Large Cell Carcinoma, Lung Squamous Cell Carcinoma, Minimally Invasive Lung Adenocarcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Interventions: 3-Dimensional Conformal Radiation Therapy, Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Placebo Administration, Veliparib; Radiation · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 232
States / cities: Anchorage, Alaska • Tucson, Arizona • Beverly Hills, California + 158 more

Conditions: Covid19
Interventions: theraputic heparin, prophylactic heparin, P2Y12, Crizanlizumab Injection, SGLT2 inhibitor; Drug
Lead sponsor: Matthew Neal MD; Other
Eligibility: 18 Years and older
Enrollment: 3,591 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 81
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more

Conditions: Acute Stroke
Interventions: endovascular sampling; Other
Lead sponsor: University of Southern California; Other
Eligibility: 40 Years to 95 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Los Angeles, California

Search by objective public record fields.

Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia

Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma

Evaluation of the BD OneFlow Acute Leukemia Panel on the BD FACSLyric Flow Cytometer

Safety and Efficacy of APG-157 in Head and Neck Cancer

Group-Based Psychological Treatments Over Video Conference for Older Veterans With Chronic Pain

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome

STeroids to REduce Systemic Inflammation After Infant Heart Surgery

Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma

Optimization of a Tenofovir Enema for HIV Prevention

18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer

Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

Emicizumab PUPs and Nuwiq ITI Study

Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia

Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)

Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant

Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer

Affective Management Training for Cannabis Misuse

Imaging Innovations for Placental Assessment in Response to Environmental Pollution (PARENTs)

A Safety/Efficacy Trial of Zonisamide for Essential Tremor

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE

Endovascular Magnesium Sampling in Acute Stroke